Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

University of Calgary

$135,000.00

In vivo imaging of host-SARS-CoV-2 interaction in the lung of mice and the role of alveolar macrophages in the disease pathogenesis.

FY 2020-21

Summary
Our immune system is the arsenal providing weapons to fight infection. In the lung, one of our most important weapons is an immune cell called the macrophage present within the air sacs or alveoli where oxygen is exchanged and any inflammation impairs this process. During respiration, humans breathe in non-sterile air daily allowing some pathogens to access the alveoli. The macrophages are like vacuum cleaners mopping up the pathogens and killing the pathogens and in maintaining the alveoli free of bacteria. During COVID-19 we think these macrophages are poisoned by the virus turning off the vacuum cleaner making us susceptible to pathogens we breathe in. When the macrophages cannot perform their job, many many immune cells race into the lungs to try to kill the bacteria. A famous scientist once described this as a bunch of hunters with grenade launchers trying to kill a duck. The likelihood of collateral damage is 100%. This is what happens when many immune cells race into the lungs to help kill the pathogens and also contribute to the generation of inflammation and lung damage. It is our hypothesis that this is what is happening but how to prove it. We have built a microscope that can look inside the lungs of living breathing mice and so we will see whether this is happening. More importantly, if it is, we have an inhibitor that will block the immune cell infiltration. We will see if it works in SARS-Cov2 infected mice and we have been given approval by the FDA to test it in COVID-19 patients. The results of this project will shed new light on our understanding of what is happening in COVID-19 patients and how best to give a specific drug to help these patients.
Program
CIHR Fellowship
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
440616
Name
Castanheira Fernanda V
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
In vivo imaging of host-SARS-CoV-2 interaction in the lung of mice and the role of alveolar macrophages in the disease pathogenesis.
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Alveolar Macrophages; Covid-19; In Vivo Imaging; Inflammation; Intravital; Lung; Sars-Cov-2; Secondary Infection
Abstract
Our immune system is the arsenal providing weapons to fight infection. In the lung, one of our most important weapons is an immune cell called the macrophage present within the air sacs or alveoli where oxygen is exchanged and any inflammation impairs this process. During respiration, humans breathe in non-sterile air daily allowing some pathogens to access the alveoli. The macrophages are like vacuum cleaners mopping up the pathogens and killing the pathogens and in maintaining the alveoli free of bacteria. During COVID-19 we think these macrophages are poisoned by the virus turning off the vacuum cleaner making us susceptible to pathogens we breathe in. When the macrophages cannot perform their job, many many immune cells race into the lungs to try to kill the bacteria. A famous scientist once described this as a bunch of hunters with grenade launchers trying to kill a duck. The likelihood of collateral damage is 100%. This is what happens when many immune cells race into the lungs to help kill the pathogens and also contribute to the generation of inflammation and lung damage. It is our hypothesis that this is what is happening but how to prove it. We have built a microscope that can look inside the lungs of living breathing mice and so we will see whether this is happening. More importantly, if it is, we have an inhibitor that will block the immune cell infiltration. We will see if it works in SARS-Cov2 infected mice and we have been given approval by the FDA to test it in COVID-19 patients. The results of this project will shed new light on our understanding of what is happening in COVID-19 patients and how best to give a specific drug to help these patients.
Competitiondate
202012
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Castanheira, Fernanda V
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~